ENYO Pharma is advancing its pipeline with Vonafexor series for diseases with impaired kidney function as CKD, Alport syndrome, NASH and DKD.

Vonafexor (EYP001)

  • Molecule: small molecule; synthetic and non-steroidal agonist of NR1H4 (farnesoid X receptor, FXR or bile acid receptor)
  • Drug profile: distributed mainly to both the kidney and the liver
  • Administration mode: oral (tablet), once a day
  • Mode of Action: fibrolytic and anti-inflammatory
  • Clinical development: supported by 9 completed clinical studies: 6 Phases 1 and 3 Phases 2a ; currently in Phase 2 for Alport syndrome and CKD in patients with NASH